Advance Search
Volume 38 Issue 9
Sep.  2022
Turn off MathJax
Article Contents
YU Na, LIU Yu-na, BAI Xiao-ling, . Adverse events following immunization among the elderly having booster COVID-19 vaccine: an active surveillance in Guiyang city[J]. Chinese Journal of Public Health, 2022, 38(9): 1113-1117. doi: 10.11847/zgggws1139515
Citation: YU Na, LIU Yu-na, BAI Xiao-ling, . Adverse events following immunization among the elderly having booster COVID-19 vaccine: an active surveillance in Guiyang city[J]. Chinese Journal of Public Health, 2022, 38(9): 1113-1117. doi: 10.11847/zgggws1139515

Adverse events following immunization among the elderly having booster COVID-19 vaccine: an active surveillance in Guiyang city

doi: 10.11847/zgggws1139515
  • Received Date: 2022-07-06
    Available Online: 2022-07-21
  • Publish Date: 2022-09-30
  •   Objective  To examine the incidence of adverse events following immunization (AEFI) among old people receiving booster dose of coronavirus disease 2019 (COVID-19) vaccine and to provide reference data for evaluating the safety of COVID-19 vaccine booster immunization in the population.   Methods  Using a self-designed questionnaire on AEFI, we conducted person-to-person telephone interviews among 1 157 vaccinees aged 60 years and above 7 – 14 days after receiving booster dose of COVID-19 vaccine at a community healthcare service station between October 2021 and March 2022.   Results  Of all the elderly interviewed, 122 (10.54%) reported AEFI. Local reaction was the most frequently reported AEFI (112 person times in 90 participants) and the majority (64.29%, 72/112 person times) of the local reactions was pain at the injection site. Of the 90 participants reporting AEFI, 58.89% (n = 53) had their adverse events spontaneously improved one or two days after the vaccination. Totally 46 person times of systemic reactions were reported by 38 participants, and 32.61% (15 person times) of the systemic reactions was fatigue; the reported systemic reactions also spontaneously improved in 21 (55.26%) of the sufferers one or two days after the vaccination. There were 6 participants reporting both local and systemic reaction. No significant association of hypertension, diabetes and hyperlipidemia with the occurrence of AEFI was observed. There was a significant difference in the incidence of AEFI among the participants having different booster immunization schedules (χ2 = 14.705, P < 0.05). Among the participants having inactivated vaccines, the incidence of AEFI was 12.59% (36/286) for those with the booster dose of homologous vaccine from the same manufacture as their routine vaccination and the incidence was 9.50% (67/705) for those with the booster dose of homologous vaccine but from different manufacture; among the participants having two doses recombinant novel coronavirus vaccine (type 5 adenovirus vector, abbreviated as adenovirus) the AEFI incidence was 13.33% (2/15); among the participants having non homologous vaccine booster dose, the AEFI incidence was 22.41% (13/58) or 4.30% (4/93) for those with the booster dose of adenovirus vaccine or recombinant novel coronavirus vaccine (CHO cell vaccine).   Conclusion  The incidence of AEFI was lower in the elderly after receiving booster dose of COVID-19 vaccine with different immunization schedules and most of the AEFI were transient, self-limiting reactions, indicating a good safety of booster immunization of COVID-19 vaccine .
  • loading
  • [1]
    Shivalkar S, Pingali MS, Verma A, et al. Outbreak of COVID-19: a detailed overview and its consequences[M]//Asea AAA, Kaur P. Coronavirus Therapeutics – Volume II: Clinical Management and Public Health. Cham: Springer, 2021: 23 – 45.
    [2]
    Ciotti M, Ciccozzi M, Pieri M, et al. The COVID - 19 pandemic: viral variants and vaccine efficacy[J]. Critical Reviews in Clinical Laboratory Sciences, 2022, 59(1): 66 – 75. doi: 10.1080/10408363.2021.1979462
    [3]
    Israel A, Shenhar Y, Green I, et al. Large - scale study of antibody titer decay following BNT162b2 mRNA vaccine or SARS - CoV - 2 infection[J]. Vaccines, 2022, 10(1): 64.
    [4]
    吕晓亚, 宋磊, 马昭, 等. 新型冠状病毒疫苗免疫策略的强化和优化[J]. 上海交通大学学报(医学版), 2021, 41(12): 1545 – 1550.
    [5]
    Pande P, Tendolkar VD, Bankar N. COVID - 19 is dangereous for old age person[J]. Journal of Critical Reviews, 2020, 7(10): 48 – 50.
    [6]
    北京商报. 60岁以上老年人接种新冠疫苗覆盖人数达2亿3231.1万人[EB/OL]. (2022 – 06 – 24)[2022 – 06 – 24]. https://www.sohu.com/a/560576080_115865.
    [7]
    陈鹏, 李春辉, 郝凤, 等. 烟台市18岁及以上人群新冠疫苗加强免疫接种意愿调查[J]. 现代预防医学, 2022, 49(4): 738 – 741.
    [8]
    卫生部办公厅, 国家食品药品监督管理局办公室. 关于印发《全国疑似预防接种异常反应监测方案》的通知[R]. 北京: 卫生部办公厅, 国家食品药品监督管理局办公室, 2010: 44 – 55.
    [9]
    张丽娜, 李克莉, 杜雯, 等. 2019年中国疑似预防接种异常反应监测[J]. 中国疫苗和免疫, 2021, 27(4): 438 – 445. doi: 10.19914/j.CJVI.2021075
    [10]
    武文娣, 李克莉, 许涤沙, 等. 中国2015 — 2018年3个流感季节流感疫苗疑似预防接种异常反应监测数据分析[J]. 中华预防医学杂志, 2019, 53(10): 987 – 992.
    [11]
    Jeon M, Kim J, Oh CE, et al. Adverse events following immuniza-tion associated with the first and second doses of the ChAdOx1 nCoV - 19 vaccine among healthcare workers in Korea[J]. Vaccines, 2021, 9(10): 1096. doi: 10.3390/vaccines9101096
    [12]
    Kant A, Jansen J, van Balveren L, et al. Description of frequencies of reported adverse events following immunization among four different COVID - 19 vaccine brands[J]. Drug Safety, 2022, 45(4): 319 – 331. doi: 10.1007/s40264-022-01151-w
    [13]
    Tran VN, Nguyen HA, Le TTA, et al. Factors influencing adverse events following immunization with AZD1222 in Vietnamese adults during first half of 2021[J]. Vaccine, 2021, 39(44): 6485 – 6491. doi: 10.1016/j.vaccine.2021.09.060
    [14]
    Supangat, Sakinah EN, Nugraha MY, et al. COVID - 19 vaccines programs: adverse events following immunization (AEFI) among medical clerkship student in Jember, Indonesia[J]. BMC Pharmac-ology and Toxicology, 2021, 22(1): 58. doi: 10.1186/s40360-021-00528-4
    [15]
    Choi YY, Kim MK, Kwon HC, et al. Safety monitoring after the BNT162b2 COVID - 19 vaccine among adults aged 75 years or older[J]. Journal of Korean Medical Science, 2021, 36(45): e318. doi: 10.3346/jkms.2021.36.e318
    [16]
    Chakraborty A, Reval N, Kamath L. Adverse events following COVID - 19 vaccination in selected apartments in Bangalore, India[J]. Cureus, 2022, 14(2): e21809.
    [17]
    Wen F, Guo JY, Li ZL, et al. Sex - specific patterns of gene expression following influenza vaccination[J]. Scientific Reports, 2018, 8(1): 13517. doi: 10.1038/s41598-018-31999-x
    [18]
    Jiang N, Gu PF, Sun X, et al. Acceptance of COVID-19 vaccines in patients with chronic diseases: a cross-sectional study[J]. Journal of Clinical Nursing, 2022, doi: 10.1111/jocn.16284.
    [19]
    容志, 秦浩. 再组织化与社会治理现代化: 重大公共卫生事件中社区“整体网格”的运行逻辑及其启示[J]. 上海行政学院学报, 2020, 21(6): 66 – 77. doi: 10.3969/j.issn.1009-3176.2020.06.007
    [20]
    Zhu FC, Jin PF, Zhu T, et al. Safety and immunogenicity of a recombinant adenovirus type - 5 - vectored coronavirus disease 2019 (COVID - 19) vaccine with a homologous prime - boost regimen in healthy participants aged ≥ 6 years: a randomized, double - blind, placebo - controlled, phase 2b trial[J]. Clinical Infectious Diseases, 2021: ciab845. doi: 10.1093/cid/ciab845
    [21]
    Zhao ZX, Cui TT, Huang MZ, et al. Heterologous boosting with third dose of coronavirus disease recombinant subunit vaccine increases neutralizing antibodies and T cell immunity against different severe acute respiratory syndrome coronavirus 2 variants[J]. Emerging Microbes and Infections, 2022, 11(1): 829 – 840. doi: 10.1080/22221751.2022.2048969
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Tables(3)

    Article views (560) PDF downloads(194) Cited by()
    Proportional views
    Publishing history
    • Receive:  2022-07-06
    • Online:  2022-07-21
    • Published:  2022-09-30

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return